Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the successful presentation of clinical data at the American Association for Cancer Research ...

The extent of residual prostate cancer in the surgical specimen following intensified neoadjuvant therapy for high-risk localized prostate cancer may predict metastatic recurrence. Residual disease ...

Immunotherapy—particularly PD-1 inhibition with cemiplimab—is reshaping CSCC care by expanding into neoadjuvant and adjuvant ...

Bladder cancer trials of antibody-drug conjugates may change the standard for neoadjuvant therapy away from dependence on cisplatin chemotherapy.

Oncologists are increasingly reaching for the prescription pad before the scalpel, driving a dramatic rise in the use of neoadjuvant therapy for solid tumors, according to new research. The second ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Matteo Carlino, ...

In this episode of The OncoloGIST, Dr Christine Bestvina of UChicago Medicine provides a comprehensive look at the rapidly ...

Ataraxis AI, a frontier artificial intelligence (AI) research lab developing AI-powered tools for oncology, today announced Ataraxis™ Breast NEO, a new predictive test within its Ataraxis Breast ...

In an interview with Targeted Oncology, Naomi Haas, MD, discusses the evolving landscape of adjuvant and neoadjuvant immune ...